Wells Fargo analyst Brandon Couillard lowered the firm’s price target on GeneDx (WGS) to $75 from $155 and keeps an Overweight rating on the shares. The firm says the company posted a much weaker-than-expected Q1 print and cut full year guide with many moving parts that caught Wells off guard. The good news is exome/genome volume remains robust, adds the firm, which expects shares to be down sharply today.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WGS:
- Genedx Earnings Call Resets Outlook Amid Strong Growth
- Closing Bell Movers: Pinterest jumps 15% on earnings beat; Palantir slips
- GeneDx reports Q1 adjusted loss ($8.2M) vs. ($9.2M) last year
- GeneDx lowers 2026 revenue outlook to $475M-$490M from $540M-$555M
- GeneDx sees Q2 revenue $110M-$112M, consensus $128.2M